Literature DB >> 34126914

Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer.

Rakesh Sahu1, Rakhi Mishra2, Rajnish Kumar2, Chandana Majee2, Avijit Mazumder2, Ajay Kumar2.   

Abstract

The incidence of cancer is increasing worldwide, affecting a vast majority of the human population, therefore, new different anticancer agents are being developed now and their safety still needs to be evaluated. Among them, pyridine based drugs are contributing a lot, as they are one of the imperative pharmacophores occurring synthetically as well as naturally in heterocyclic compounds, having a wide-range of therapeutic applications in the area of drug discovery that offers many chances for further improvement in antitumor agents via acting onto numerous receptors of extreme prominence. Many pyridine derivatives are reported to inhibit enzymes, receptors and many other targets for controlling and curing the global health issue of cancer. Nowadays in combination with other moieties, researchers are focusing on the development of pyridine-based new derivatives for cancer treatment. Therefore, this review sheds light on the recent therapeutic expansion of pyridine together with its molecular docking, structure-activity-relationship, availability in the market, a summary of recently patented and published research works that shall jointly help the scientists to produce effective drugs with the desired pharmacological activity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Pyridine moiety; WHO.; anticancer; cancer treatment; heterocyclic compound; structure-activity relationships (SAR)

Mesh:

Substances:

Year:  2022        PMID: 34126914     DOI: 10.2174/1389557521666210614162031

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  1 in total

1.  Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer.

Authors:  Bo Qin; Qian Bai; Dan Yan; Fanxiang Yin; Zhu Zhu; Chaoyuan Xia; Yang Yang; Yi Zhao
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.